A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Inclusion Criteria: * 12 years to 60 years, male. * The activity of the coagulation factor VIII (FVIII:C) \< 2%, and previously treated with FVIII concentrate (s) for a minimum of 150 exposure days (EDs) prior to study entry. * Non-immune deficiency (CD4 \> 200/μL). * Non-acute hemorrhagic state. * No history of a positive inhibitor test (\< 0.6 BU) or clinical signs of decreased response to FVIII administrations. No Family history of inhibitors. * Platelet count \> 100,000 platelets/μL. * Normal prothrombin time or INR \< 1.3. * Normal thrombin time (TT). * Normal previous results of vWF antigen examination. * Negative lupus anticoagulant . * Capable of understanding and willing to comply with the conditions of the protocol have read (patient and/or guardian). Exclusion Criteria: * Hypersensitive to any of the excipients of the test materials (e.g. allergic to murine or hamster origin heterologous proteins). * History of hypersensitivity or anaphylaxis associated with any FVIII or IgG2 administration. * Current FVIII inhibitor-positive or history of FVIII inhibitor-positive. * Other coagulation disorder(s) in addition to hemophilia A. * Infusion of any products containing FVIII within 4 days prior screening or within 72 h prior to administration. * Patients with severe heart disease, including myocardial infarction, heart failure (III or higher level). * Clinically significant of other systematic diseases: alcoholism, drug abuse, mental disorders and mental retardation. * Significant hepatic or renal impairment (ALT and AST \> 2×ULN; serum bilirubin level \> 3 × upper limit of normal (ULN) , BUN \> 2×ULN, Cr \> 2.0 mg/dL). * One or more clinically significant tests for Human Immunodeficiency Virus (HIV), Antisyphilitic spirulina (TPHA) and Hepatitis C Virus (HCV) Antibody. * Patients who received any anticoagulant or antiplatelet therapy within one week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials. * Patients having major surgery or receiving blood or bood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study. * Patients who previously participated in the other clinical trials within 1 month prior screening. * Any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation. * Patient who is considered by the other investigators not suitable for clinical study.